Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
Calgary, Alberta (ots/PRNewswire) - The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million Resverlogix Corp. ("Resverlogix" or the "Company") today announced that it has entered into a Framework ...